急性缺血性卒中的溶栓治疗进展  

Advances in Thrombolytic Therapy of Acute Ischemic Stroke

作　　者：姜宏[1] 王颖[2] 汤克仁[1] 

机构地区：[1]山东省淄博市中心医院神经内科,255036 [2]解放军第148医院内科,淄博255300

出　　处：《国外医学（脑血管疾病分册）》2005年第11期827-830,共4页Foreign Medical Sciences Cerebrovascular Diseases

摘　　要：重组组织型纤溶酶原激活剂静脉溶栓是目前惟一一种证实有效的治疗急性缺血性卒中的药物。在许多情况下,费用低廉的尿激酶不失为一种较好的选择。虽然溶栓治疗日趋成熟,但一些问题仍需进一步探讨,如新的溶栓药物用于发病3h以上的急性缺血性卒中患者、评价各种新的再灌注方法、静脉和动脉内药物溶栓联合应用、溶栓和新型抗小板药的联合应用,以及应用机械装置或经颅多普勒超声促进药物溶栓的作用等等。Recombinant tissue plasminogen activator （rtPA） is currently the only available drug that has been confirmed to be effective for acute ischemic＇stroke. Under many circumstances, a cheaper uroldnase may after all be accepted as a good choice. Although thrombolytic therapy is becoming perfect gradually, some problems should be further discussed, for example, new thrombolytic agents to be used in the onset of stroke more than 3 hours in patients with acute ischemic stroke; the assessment of various new reperfusion approaches; the combination of intravenous and intra-arterial thrombolytic agents; the combination thrombolytics with new antiplateletagents, and the application of mechanical devices or transcranial Doppler ultrasound in promoting the effect of thrombolysis and so on.

关 键 词：急性缺血性卒中 溶栓 辅助治疗 

分 类 号：R743.3[医药卫生—神经病学与精神病学]